If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. Besides EGF itself other family members include:
We have no involvement in the operations you were referring to." United Kingdom officials refused to comment on an 11 November CNN report that the UK had suspended intelligence sharing with the US about suspected drug trafficking vessels over the risks of being complicit in the strikes, which it reportedly believes are illegal. A spokesperson for Prime Minister Keir Starmer stated that "the US is our closest partner on defense, security, intelligence", while declining to comment on intelligence matters. Rubio denied the CNN report, calling it a "false story". Yvette Cooper, the UK foreign secretary, responded that intelligence sharing continues, and referenced Rubio's comment about the "false story". Amid increasing tensions, many European high-level leaders canceled their planned participation in a November summit held in Colombia between the European Union and the Community of Latin American and Caribbean States (CELAC), in contrast to the 2023 EU–CELAC summit attended by numerous heads of state. According to Pino Arlacchi, the former head of the UN Office on Drugs and Crime, the portrayal of Venezuela as a "drug state" is a "geopolitically motivated smear campaign" by the US government; he refers to the World Drug Report 2025 and states that the Venezuelan government's cooperation in the fight against drug trafficking is among the best in South America. His view is that the US has taken an interest in Venezuelan oil reserves, which are among the largest in the world.
== Nanofactories == A nanofactory is a proposed system in which nanomachines (resembling molecular assemblers, or industrial robot arms) would combine reactive molecules via mechanosynthesis to build larger atomically precise parts. These, in turn, would be assembled by positioning mechanisms of assorted sizes to build macroscopic (visible) but still atomically-precise products. A typical nanofactory would fit in a desktop box, in the vision of K. Eric Drexler published in Nanosystems: Molecular Machinery, Manufacturing and Computation (1992), a notable work of "exploratory engineering". During the 1990s, others have extended the nanofactory concept, including an analysis of nanofactory convergent assembly by Ralph Merkle, a systems design of a replicating nanofactory architecture by J. Storrs Hall, Forrest Bishop's "Universal Assembler", the patented exponential assembly process by Zyvex, and a top-level systems design for a 'primitive nanofactory' by Chris Phoenix (director of research at the Center for Responsible Nanotechnology). All of these nanofactory designs (and more) are summarized in Chapter 4 of Kinematic Self-Replicating Machines (2004) by Robert Freitas and Ralph Merkle. The Nanofactory Collaboration, founded by Freitas and Merkle in 2000, is a focused, ongoing effort involving 23 researchers from 10 organizations and 4 countries that is developing a practical research agenda specifically aimed at positionally-controlled diamond mechanosynthesis and diamondoid nanofactory development.
GLP-1 Formula – a formulation intended to support endogenous glucagon-like peptide-1 (GLP-1) activity. The GLP-1 Formula is a proprietary blend of plant extracts, probiotics, and prebiotics developed to support endogenous glucagon-like peptide-1 (GLP-1) activity. GLP-1 is a hormone secreted by intestinal L-cells in response to food intake that regulates insulin secretion, suppresses glucagon release, reduces appetite, and slows gastric emptying. TCI leveraged its Bio-Resource Data Mining technology to identify natural active compounds, and subsequently developed the formula through in-vitro validations and human trials. In-vitro studies indicated that the formula stimulates natural GLP-1 secretion from intestinal L-cells, which TCI reported to support stable blood glucose levels, enhances fat metabolism, and may induce white fat browning. SugarLock – a botanical extract designed to modulate postprandial glucose response. It is described as a proprietary, polyphenol-rich, allergen-free extract, and in clinical evaluation over a six-week intervention period was shown to support fasting blood glucose, decrease body fat, and attenuate postprandial blood sugar spikes. Outcomes were further validated through continuous glucose monitoring (CGM). TCI has positioned SugarLock as an ingredient for brands targeting glycemic control and metabolic health applications. The ingredient was featured at SupplySide Global 2025, where TCI's Chief Product Officer presented clinical findings from the intervention study.
Sources: en.wikipedia.org
Requires Supplemental Nutrition Assistance Program (federal food assistance) beneficiaries ages 18 to 64 to work at least 80 hours per month, compared to ages 18 to 54 under current law; Requires states with an error rate above 6% to contribute to up to 15% of SNAP benefit costs. Alaska and Hawaii received special exemptions for these effective cuts after lobbying from senators Lisa Murkowski and Dan Sullivan; Repeals the National Education and Obesity Prevention Grant Program; Reduces federal nutrition funding by $186 billion between 2025 and 2034. Increases the share of state costs to administer the SNAP program from 50% to 75%; and Restricts future updates to the Thrifty Food Plan used to calculate SNAP benefit levels.
As of 2022, TikTok is the 10th most popular app in Russia. After a new set of Russian war censorship laws was installed in March 2022, the company announced a series of restrictions on Russian and non-Russian posts and livestreams. Tracking Exposed, a user data rights group, learned of what was likely a technical glitch that became exploited by pro-Russia posters. It stated that although this and other loopholes were patched by TikTok before the end of March, the initial failure to correctly implement the restrictions, in addition to the effects from Kremlin's "fake news" laws, contributed to the formation of a "splInternet ... dominated by pro-war content" in Russia. TikTok said that it had removed 204 accounts for swaying public opinion about the war while obscuring their origins and that its fact checkers had removed 41,191 videos for violating its misinformation policies. In December 2023, BBC News reported that it had discovered nearly 800 fake TikTok accounts promoting Russian propaganda and disinformation. TikTok's own investigation found more than 12,000 fake accounts, including ones using additional languages such as English and Italian. In September 2024, TikTok removed the accounts of Russian state media outlets RT and Sputnik.
=== Category:EC 2.3 (acyltransferases) === Category:EC 2.3.1 Aminolevulinic acid synthase EC 2.3.1.37 Choline acetyltransferase EC 2.3.1.6 Category:EC 2.3.2 Factor XIII EC 2.3.2.13 Gamma glutamyl transpeptidase EC 2.3.2.2 Transglutaminase EC 2.3.2.13
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.